Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035704995> ?p ?o ?g. }
- W3035704995 endingPage "838" @default.
- W3035704995 startingPage "829" @default.
- W3035704995 abstract "Background Diacylglycerol-O-acyltransferase 2 (DGAT2) is one of two enzyme isoforms that catalyse the final step in the synthesis of triglycerides. IONIS-DGAT2Rx is an antisense oligonucleotide inhibitor of DGAT2 that is under clinical investigation for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The aim of this trial was to examine the safety, tolerability, and efficacy of IONIS-DGAT2Rx versus placebo in reducing liver fat in patients with type 2 diabetes and NAFLD. Methods This double-blind, randomised, placebo-controlled, phase 2 study consisted of a 2-week screening period, a run-in period of up to 4 weeks, a 13-week treatment period of once-weekly dosing, and a 13-week post-treatment follow-up period. The study was done at 16 clinical research sites in Canada, Poland, and Hungary. Eligible participants were aged 18–75 years, had a body-mass index at screening between 27 kg/m2 and 39 kg/m2, haemoglobin A1c (HbA1c) levels from 7·3% to 9·5%, and liver fat content 10% or greater before randomisation, and agreed to maintain a stable diet and exercise routine throughout the study. Enrolled participants were stratified on the basis of liver fat content during the run-in period (<20% or ≥20%) and then centrally randomised (2:1) to receive once weekly subcutaneous injection of 250 mg IONIS-DGAT2Rx or placebo for 13 weeks. Participants, investigators, funder personnel, and the clinical research organisation staff, including central readers of MRI scans, were all masked to treatment identity. The primary endpoints were the safety, tolerability, and pharmacodynamic effect of IONIS-DGAT2Rx on hepatic steatosis, according to absolute reduction from baseline in liver fat percentage as quantified by MRI-estimated proton density fat fraction and assessed in the per-protocol population. Pharmacodynamic performance was determined in the per-protocol population by the change in liver fat content from baseline to 2 weeks after the last dose. The per-protocol population included all randomised participants who received at least ten doses of study drug, with the first four doses administered in the first 5 weeks, did not miss more than three consecutive weekly doses, and who had no protocol deviations that might affect efficacy. All randomised participants who received at least one dose of study drug were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT03334214. Findings Between Nov 3, 2017, and Nov 28, 2018, we screened 173 people for eligibility. 44 were enrolled and randomly assigned to receive either IONIS-DGAT2Rx (29 participants) or placebo (15 participants). After 13 weeks of treatment, the mean absolute reduction from baseline was −5·2% (SD 5·4) in the IONIS-DGAT2Rx group compared with −0·6% (6·1) in the placebo group (treatment difference −4·2%, 95% CI −7·8 to −0·5, p=0·026). Reductions in liver fat were not accompanied by hyperlipidaemia, elevations in serum aminotransferases or plasma glucose, changes in bodyweight, or gastrointestinal side-effects compared with placebo. Six serious adverse events occurred in four patients treated with IONIS-DGAT2Rx. No serious adverse events were reported in the placebo group. One of four patients reported three serious adverse events: acute exacerbation of chronic obstructive pulmonary disease, cardiac arrest, and ischaemic cerebral infarction, each considered severe and not related to study drug. Three of four patients reported one serious adverse event of increased blood triglycerides (severe, unrelated to study drug), deep-vein thrombosis (severe, unlikely to be related to study drug), and acute pancreatitis (mild, unrelated to study drug). Interpretation Our results suggest that DGAT2 antisense inhibition could be a safe and efficacious strategy for treatment of NAFLD and support further investigation in patients with biopsy-proven NASH. Based on the pharmacological target, the response to treatment observed in this study population could extend to the broader population of patients with NAFLD. Funding Ionis Pharmaceuticals." @default.
- W3035704995 created "2020-06-19" @default.
- W3035704995 creator A5004073231 @default.
- W3035704995 creator A5027088501 @default.
- W3035704995 creator A5039227038 @default.
- W3035704995 creator A5044577761 @default.
- W3035704995 creator A5052059601 @default.
- W3035704995 creator A5056554811 @default.
- W3035704995 creator A5088325447 @default.
- W3035704995 creator A5091158941 @default.
- W3035704995 date "2020-09-01" @default.
- W3035704995 modified "2023-10-15" @default.
- W3035704995 title "Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial" @default.
- W3035704995 cites W1614032175 @default.
- W3035704995 cites W1926691574 @default.
- W3035704995 cites W1976094170 @default.
- W3035704995 cites W1997425045 @default.
- W3035704995 cites W2012675392 @default.
- W3035704995 cites W2013507231 @default.
- W3035704995 cites W2033396762 @default.
- W3035704995 cites W2039481955 @default.
- W3035704995 cites W2047257800 @default.
- W3035704995 cites W2049610959 @default.
- W3035704995 cites W2054600904 @default.
- W3035704995 cites W2065612971 @default.
- W3035704995 cites W2070098406 @default.
- W3035704995 cites W2080134484 @default.
- W3035704995 cites W2086113980 @default.
- W3035704995 cites W2138306815 @default.
- W3035704995 cites W2164118055 @default.
- W3035704995 cites W2169894356 @default.
- W3035704995 cites W2204688218 @default.
- W3035704995 cites W2210672989 @default.
- W3035704995 cites W2237544788 @default.
- W3035704995 cites W2462595066 @default.
- W3035704995 cites W2580009538 @default.
- W3035704995 cites W2625846788 @default.
- W3035704995 cites W2626867658 @default.
- W3035704995 cites W2734724639 @default.
- W3035704995 cites W2772777089 @default.
- W3035704995 cites W2793275191 @default.
- W3035704995 cites W2883362011 @default.
- W3035704995 cites W2899595328 @default.
- W3035704995 cites W2905440332 @default.
- W3035704995 cites W2906651560 @default.
- W3035704995 cites W2936295302 @default.
- W3035704995 cites W2936788966 @default.
- W3035704995 cites W2938096756 @default.
- W3035704995 cites W2955615964 @default.
- W3035704995 cites W2973125925 @default.
- W3035704995 doi "https://doi.org/10.1016/s2468-1253(20)30186-2" @default.
- W3035704995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32553151" @default.
- W3035704995 hasPublicationYear "2020" @default.
- W3035704995 type Work @default.
- W3035704995 sameAs 3035704995 @default.
- W3035704995 citedByCount "53" @default.
- W3035704995 countsByYear W30357049952020 @default.
- W3035704995 countsByYear W30357049952021 @default.
- W3035704995 countsByYear W30357049952022 @default.
- W3035704995 countsByYear W30357049952023 @default.
- W3035704995 crossrefType "journal-article" @default.
- W3035704995 hasAuthorship W3035704995A5004073231 @default.
- W3035704995 hasAuthorship W3035704995A5027088501 @default.
- W3035704995 hasAuthorship W3035704995A5039227038 @default.
- W3035704995 hasAuthorship W3035704995A5044577761 @default.
- W3035704995 hasAuthorship W3035704995A5052059601 @default.
- W3035704995 hasAuthorship W3035704995A5056554811 @default.
- W3035704995 hasAuthorship W3035704995A5088325447 @default.
- W3035704995 hasAuthorship W3035704995A5091158941 @default.
- W3035704995 hasConcept C126322002 @default.
- W3035704995 hasConcept C142724271 @default.
- W3035704995 hasConcept C197934379 @default.
- W3035704995 hasConcept C203092338 @default.
- W3035704995 hasConcept C204787440 @default.
- W3035704995 hasConcept C27081682 @default.
- W3035704995 hasConcept C2777214474 @default.
- W3035704995 hasConcept C2777575235 @default.
- W3035704995 hasConcept C2778375690 @default.
- W3035704995 hasConcept C2778772119 @default.
- W3035704995 hasConcept C2779134260 @default.
- W3035704995 hasConcept C535046627 @default.
- W3035704995 hasConcept C71924100 @default.
- W3035704995 hasConcept C90924648 @default.
- W3035704995 hasConceptScore W3035704995C126322002 @default.
- W3035704995 hasConceptScore W3035704995C142724271 @default.
- W3035704995 hasConceptScore W3035704995C197934379 @default.
- W3035704995 hasConceptScore W3035704995C203092338 @default.
- W3035704995 hasConceptScore W3035704995C204787440 @default.
- W3035704995 hasConceptScore W3035704995C27081682 @default.
- W3035704995 hasConceptScore W3035704995C2777214474 @default.
- W3035704995 hasConceptScore W3035704995C2777575235 @default.
- W3035704995 hasConceptScore W3035704995C2778375690 @default.
- W3035704995 hasConceptScore W3035704995C2778772119 @default.
- W3035704995 hasConceptScore W3035704995C2779134260 @default.
- W3035704995 hasConceptScore W3035704995C535046627 @default.
- W3035704995 hasConceptScore W3035704995C71924100 @default.
- W3035704995 hasConceptScore W3035704995C90924648 @default.
- W3035704995 hasFunder F4320337357 @default.